ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future

Rankin, Naomi J.*; Preiss, David; Welsh, Paul; Sattar, Naveed
International Journal of Epidemiology2016-10DOI: 10.1093/ije/dyw271
18被引1阅读
引用收藏
分享

摘要

Metabolomics and lipidomics are emerging methods for detailed phenotyping of small molecules in samples. It is hoped that such data will: (i) enhance baseline prediction of patient response to pharmacotherapies (beneficial or adverse); (ii) reveal changes in metabolites shortly after initiation of therapy that may predict patient response, including adverse effects, before routine biomarkers are altered; and(iii) give new insights into mechanisms of drug action, particularly where the results of a trial of a new agent were unexpected, and thus help future drug development. In these ways, metabolomics could enhance research findings from intervention studies. This narrative review provides an overview of metabolomics and lipidomics in early clinical intervention studies for investigation of mechanisms of drug action and prediction of drug response (both desired and undesired). We highlight early examples from drug intervention studies associated with cardiometabolic disease. Despite the strengths of such studies, particularly the use of state-of-the-art technologies and advanced statistical methods, currently published studies in the metabolomics arena are largely underpowered and should be considered as hypothesis-generating. In order for metabolomics to meaningfully improve stratified medicine approaches to patient treatment, there is a need for higher quality studies, with better exploitation of biobanks from randomized clinical trials i.e. with large sample size, adjudicated outcomes, standardized procedures, validation cohorts, comparison witth routine biochemistry and both active and control/placebo arms. On the basis of this review, and based on our research experience using clinically established biomarkers, we propose steps to more speedily advance this area of research towards potential clinical impact.

学科与关键词

关键词
Metabolomicslipidomicspharmacometabolomicsclinical trialsintervention studiescardiovascular diseasediabetes
相关
加载中…
  • The emerging role of plasma lipidomics in cardiovascular drug discovery
    Puri, Rishi; MyNgan Duong; Uno, Kiyoko; Kataoka, Yu; Nicholls, Stephen J.*Expert Opinion on Drug Discovery, 2012, 7(1): 63-72.被引 19
  • Potential of metabolomics in preclinical and clinical drug development
    Kumar, Baldeep; Prakash, Ajay; Ruhela, Rakesh Kumar; Medhi, Bikash*Pharmacological Reports, 2014, 66(6): 956-963.被引 29
  • Metabolomics toward personalized medicine
    Jacob, Minnie; Lopata, Andreas L.; Dasouki, Majed; Rahman, Anas M. Abdel*Mass Spectrometry Reviews, 2019, 38(3): 221-238.被引 236
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of Epidemiology
发表日期
2016-10
卷期
第 45 卷, 第 5 期
页码
1351-1371
DOI
10.1093/ije/dyw271
语言
ENGLISH
成果收录
SCIE
资助标注
UPBEAT RCT mother-child study; Medical Research Council (MRC) [MR/L002477/1]; Chief Scientist Office, Scotland [CZB/4/613]; Wellcome Trust Institutional Strategic Support Fund (ISSF) [WT097821MF]; European Federation of Pharmaceutical Industries Associations (EFPIA) Innovative Medicines Initiative Joint Undertaking (EMIF) [115372]; Chest, Heart & Stroke, Scotland [R13/A149]; European commission [305507]; MRC [MR/L002477/1] Funding Source: UKRI

作者

  • R

    Rankin, Naomi J. (通讯) (第一作者)

  • P

    Preiss, David

查看全部 4 位作者收起作者
  • W

    Welsh, Paul

  • S

    Sattar, Naveed

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417